Source: Health Canada shortage reports · Updated Oct 27, 2026
Some Alirocumab products are in shortage in Canada (1 of 3 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 4, 2026.
A PCSK9 inhibitor used to lower high cholesterol.
Products affected
1 / 3
In shortage since
Oct 23, 2026
Est. full return
Dec 4, 2026
Reports on file
16
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · since Oct 23, 2026, est. end Dec 4, 2026
Resolved
PRALUENT
300MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02547732 · ended Aug 13, 2026
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Feb 6, 2026
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Jun 5, 2024 · Manufacturing Delay
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Dec 22, 2023
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Dec 22, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended May 31, 2023 · Manufacturing delay.
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Feb 2, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Jan 26, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Dec 22, 2022 · Demand increase for the drug.
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Nov 8, 2021
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended May 3, 2021 · A manufacturing delay may create a short term shortage. Supplies are expected by early May, shortage should be avoided as allocation will be put in place.
Showing 12 of 16 reports. All reports are on file with Health Canada.
What's happening
Alirocumab is currently affected by an active shortage report filed with Health Canada by SANOFI-AVENTIS CANADA INC.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Alirocumab is classified under “LIPID MODIFYING AGENTS, PLAIN” (ATC C10AX).
Recent changes
Oct 27, 2026
Status changed
Oct 23, 2026
New report filed
Aug 17, 2026
Shortage resolved
Aug 7, 2026
Estimated end date pushed back : Aug 7, 2026 → Aug 14, 2026
Jul 31, 2026
Status changed
Jul 31, 2026
Estimated end date pushed back : Jul 31, 2026 → Aug 7, 2026
Jul 29, 2026
New report filed
Common questions
What is Alirocumab used for?
A PCSK9 inhibitor used to lower high cholesterol.
When will Alirocumab be back in stock in Canada?
The latest manufacturer estimate is Dec 4, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Alirocumab in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.